
    
      A single group of approximately 12 HIV-infected subjects will receive a 4 dose series of
      PENNVAX-B containing 3 mg of DNA/dose at study entry (Day 0), Week 4, 8, 16 and will be
      followed for a total of 48 weeks.
    
  